CJC-1295 won't be found on pharmacy shelves in Yuni or virtually any local market — it's a research compound supplied via a dedicated online market. This global online supply model is actually an advantage for quality — top vendors distinguish themselves through rigorous testing in ways no local retailer can match. What consistently distinguishes top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety documentation. The sections below cover what Yuni researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Yuni studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Sourcing Research-Grade CJC-1295
Before evaluating any specific vendor, establish a quality benchmark — so you can recognise whether a vendor meets it. A COA for CJC-1295 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. The combination of community reputation data and your own COA analysis is the gold standard for CJC-1295 sourcing — community feedback surfaces recurring issues no single purchase reveals, and vice versa. Keep lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.
Order CJC-1295 — ships to Yuni
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Temperature excursions — even temporary temperature deviation — can compromise product integrity without visible changes; always maintain cold chain and work with cold-shipped material. The primary quality-related safety risk in CJC-1295 research is endotoxin contamination from poor sourcing — a documented endotoxin result in your specific batch certificate is the specific protection against this risk. PubMed represent the most comprehensive research databases for CJC-1295 research; focus on peer-reviewed publications with documented compound quality over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
